Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly Cdr [Cad Hedged] (LLY.NE)

Eli Lilly Cdr [Cad Hedged] (LLY.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,309,079,669
  • Shares Outstanding, K 32,810,951
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 15.30
  • Price/Cash Flow 56.61
  • Price/Book 37.98
  • Price/Earnings ttm 49.47
  • Earnings Per Share ttm 0.56
  • Most Recent Earnings $0.17 on 10/30/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) 0.25 (0.57%)
  • Most Recent Dividend 0.063 on 02/13/26
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.5800 +7.93%
on 12/10/25
40.4900 -5.16%
on 11/27/25
+0.8800 (+2.35%)
since 11/18/25
3-Month
26.0200 +47.58%
on 09/25/25
40.4900 -5.16%
on 11/27/25
+10.5100 (+37.68%)
since 09/18/25
52-Week
22.8500 +68.05%
on 08/08/25
40.4900 -5.16%
on 11/27/25
+9.9000 (+34.74%)
since 12/18/24

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

See More

Key Turning Points

3rd Resistance Point 40.7300
2nd Resistance Point 39.9600
1st Resistance Point 39.1800
Last Price 38.4000
1st Support Level 37.6300
2nd Support Level 36.8600
3rd Support Level 36.0800

See More

52-Week High 40.4900
Last Price 38.4000
Fibonacci 61.8% 33.7515
Fibonacci 50% 31.6700
Fibonacci 38.2% 29.5885
52-Week Low 22.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar